|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
All study participants did not have prior heart failure or use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) up to 5 years prior.
|
31843974 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the association between prescribed ACE inhibitors and dietary sodium density in patients with HF.
|
30855313 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therapy with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is a mainstay of treatment for heart failure (HF), diabetes mellitus (DM) and chronic kidney disease (CKD).
|
31663151 |
2020 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Inhibition of RAAS using angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) have shown to significantly reduce morbidity and mortality due to HF.
|
31433752 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We illustrate the merits of our proposed approach with a detailed analysis of two large clinical trials (N = 6769) for the prevention and treatment of congestive heart failure using an angiotensin-converting enzyme inhibitor.
|
30052809 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Until recently, the combination of beta-blockers, reninangiotensin system inhibitors (angiotensin converting enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARBs)), and mineralocorticoid receptor antagonists (MRAs) formed the foundation of "triple therapy" for heart failure.
|
31736333 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, the pathological involvement of Angiotensin-converting enzyme 1 (ACE1)/angiotensin II (Ang II)/angiotensin II type 1 (AT1) axis and beneficial ACE2/Ang (1-7)/Mas receptor axis also shows protective role via Gi βγ, during heart failure these receptors get desensitized or internalized due to increase in the activity of G-protein-coupled receptor kinase 2 (GRK2) and GRK5, responsible for phosphorylation of G-protein-mediated down regulatory signaling.
|
31785110 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conducted a retrospective cohort study including consecutive adult patients followed at the HF clinic of a tertiary care center who had already been on an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB).
|
31665724 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The angiotensin-converting enzyme inhibitor enalapril is commonly used to treat chronic heart failure in children.
|
31411383 |
2020 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
HF drug exposure-beta blockers (BB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone antagonists (AA), diuretics, digoxin, or ivabradine-was assessed quarterly using a Proportion of Days Covered ≥ 66% (≥ 60 days out of the 90 days of the quarter), by considering HF drugs individually or in combination.
|
31637454 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Classic RAS blockers such as angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent AF by affecting the accumulation of the EAT, representing a useful therapeutic strategy for preventing AF especially in patients with heart failure and known left ventricular dysfunction.
|
31375968 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Beta-adrenergic blockers and angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) have been the mainstay of treatment for heart failure patients with reduced left ventricular ejection fraction for many years.
|
31008768 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chronic treatment of hypertension or heart failure very often includes an angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) as renin-angiotensin system inhibitors (RASi) treatments.
|
30836981 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Various medications used in the treatment of HF such as loop diuretics and angiotensin converting enzyme inhibitors have not demonstrated a reduction in sudden cardiac death (SCD); however, beta-blockers (BB) are effective in reducing mortality and SCD.
|
31598875 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors were more protective in the advancement and/or hospitalization of the hypertensive patient for heart failure than angiotensin receptor blockers.
|
30518809 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy reduced the odds of heart failure events by 29% (0.71, 0.61 to 0.83, P<0.001; I<sup>2</sup>=0%, P=0.78).
|
30296880 |
2019 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Whether FGF23 is associated with increased HF risk in populations with hypertension and whether this association is weaker in the presence of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy is unknown.
|
30256890 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure.
|
31498767 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hypotension risk factors included high healthcare utilisation (proxy measure for HF severity and general comorbidity; eg, ≥10 primary care physician visits versus none, odds ratio (OR): 2.29; 95% CI: 1.34-3.90), previous hypotensive episodes (OR: 2.32; 95% CI: 1.84-2.92), renal failure and use of aldosterone antagonists, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
|
31300503 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, we demonstrate the proposed method using data from a clinical study on angiotensin converting enzyme inhibitor for treating congestive heart failure.
|
30883861 |
2019 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In men, the lowest hazards of death or hospitalisation for heart failure occurred at 100% of the recommended dose of ACE inhibitors or ARBs and β blockers, but women showed approximately 30% lower risk at only 50% of the recommended doses, with no further decrease in risk at higher dose levels.
|
31447116 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We analyzed participants from PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF) with an available physical examination at baseline.
|
31510768 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Eligibility for sacubitril/valsartan initiation was based on inclusion and exclusion criteria from the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Converting-Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial and the VA Criteria for Use.
|
31498903 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Benazepril, a common ACE inhibitor, widely used in the treatment of arterial hypertension and congestive heart failure.
|
30594849 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our ten-year follow-up analysis indicated that selenium supplementation, specifically combined with the use of angiotensin-converting enzyme inhibitor and beta blocker therapy, improved the survival of patients with chronic Keshan disease with congestive heart failure.
|
31016516 |
2019 |